(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) slid by a staggering 21.65% in 10 sessions from $8.96 at 2023-04-19, to $7.02 at 12:52 EST on Wednesday, following the last session’s downward trend. NASDAQ is jumping 0.35% to $12,123.12, after two consecutive sessions in a row of losses.
Novavax’s last close was $7.04, 90.83% under its 52-week high of $76.77.
About Novavax
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.68.
Volatility
Novavax’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.79%, a negative 0.25%, and a positive 4.35%.
Novavax’s highest amplitude of average volatility was 3.04% (last week), 4.93% (last month), and 4.35% (last quarter).
Volume
Today’s last reported volume for Novavax is 1106016 which is 81.33% below its average volume of 5770080.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Novavax’s EBITDA is -0.17.
Moving Average
Novavax’s worth is below its 50-day moving average of $7.63 and way below its 200-day moving average of $20.37.
More news about Novavax (NVAX).
